LON:MXCT MaxCyte (MXCT) Share Price, News & Analysis GBX 350 +1.00 (+0.29%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range 340▼ 35650-Day Range 296▼ 40052-Week Range 180▼ 430Volume969 shsAverage Volume26,780 shsMarket Capitalization£365.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get MaxCyte alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About MaxCyte Stock (LON:MXCT)MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Read More MXCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MXCT Stock News HeadlinesJuly 25 at 5:16 AM | americanbankingnews.comMaxCyte (LON:MXCT) Share Price Passes Below Fifty Day Moving Average of $351.29May 23, 2024 | finance.yahoo.comWith 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional ownersJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 13, 2024 | seekingalpha.comMaxCyte, Inc. (MXCT) Q1 2024 Earnings Call TranscriptMay 12, 2024 | finance.yahoo.comMaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call TranscriptApril 4, 2024 | finance.yahoo.comNotice of Annual General Meeting of Vicore Pharma Holding AB (publ)March 14, 2024 | finance.yahoo.comMaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | finance.yahoo.comMaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five yearsJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.March 12, 2024 | finance.yahoo.comMaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023March 11, 2024 | markets.businessinsider.comMaxCyte earnings: here's what Wall Street expectsMarch 11, 2024 | benzinga.comMaxCyte Earnings PreviewJanuary 27, 2024 | msn.comMaxCyte Inc Announces Cenk Sumen’s Transition and Severance TermsJanuary 9, 2024 | finanznachrichten.deMaxCyte, Inc.: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial ResultsJanuary 8, 2024 | msn.comMaxCyte says Q4 revenue is expected to be between $15.5M and $15.7MJanuary 8, 2024 | finance.yahoo.comMaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial ResultsJanuary 3, 2024 | msn.comMaxCyte and Lion TCR join hands for Lion TCR's global expansionDecember 12, 2023 | bizjournals.comLongtime MaxCyte CEO Doug Doerfler to retire; Maher Masoud tapped as successorSee More Headlines Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryBusiness Services Current SymbolLON:MXCT CUSIPN/A CIKN/A Webwww.maxcyte.com Phone+1-301-9441700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-36,570,000.00 Net Margins-83.00% Pretax MarginN/A Return on Equity-15.42% Return on Assets-10.98% Debt Debt-to-Equity Ratio8.23 Current Ratio13.26 Quick Ratio14.38 Sales & Book Value Annual Sales£44.05 million Price / Sales8.31 Cash FlowGBX 177.48 per share Price / Cash Flow1.97 Book ValueGBX 217 per share Price / Book1.61Miscellaneous Outstanding Shares104,540,000Free FloatN/AMarket Cap£365.89 million OptionableNot Optionable Beta1.07 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Maher Masoud (Age 48)President, CEO, Secretary & Director Comp: $484.7kMr. Douglas Arthur Doerfler (Age 68)Founder Comp: $950.01kMr. Douglas J. Swirsky CFA (Age 55)CPA, Chief Financial Officer Mr. Jay GelfmanSenior Vice President of OperationsMr. Ronald Evan Holtz CPA (Age 66)Ph.D., Executive Vice President of Administration Comp: $514.26kMr. Sean MenarguezDirector of Investor RelationsMr. David SandovalSenior Vice President & General CounselMr. Thomas Michael Ross (Age 63)Executive Vice President of Global Sales Mr. Jack HorganVice President of Corporate DevelopmentMs. Jill MayerSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsResolute MiningLON:RSGOcean WilsonsLON:OCNChesnaraLON:CSNTremor InternationalLON:TRMRAccrol GroupLON:ACRLView All CompetitorsInsidersJohn JohnstonSold 5,000 sharesTotal: £2.21 M ($441.00/share)John JohnstonSold 200 sharesTotal: £90,600.00 ($453.00/share)John JohnstonSold 118 sharesTotal: £56,640.00 ($480.00/share)View All Insider Transactions MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed this year? MaxCyte's stock was trading at GBX 352.50 at the start of the year. Since then, MXCT stock has decreased by 0.7% and is now trading at GBX 350. View the best growth stocks for 2024 here. How do I buy shares of MaxCyte? Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), Astrotech (ASTC), Arcturus Therapeutics (ARCT), Aptose Biosciences (APTO). This page (LON:MXCT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.